FTC Sues Major PBMs Over Alleged Inflated Insulin Prices, Citing Anticompetitive Practices

Shortly after releasing a scathing interim report in July that revealed how three players dominate the pharmacy benefit manager (PBM) market and raise drug costs for patients, the Federal Trade Commission (FTC) is turning its words into action.

Late last week, the agency sued the three largest PBMs — CVS Caremark, Express Scripts, and Optum Rx — and their affiliated group purchasing organizations for “engaging in anticompetitive and unfair rebating practices” related to insulin. The FTC argues that these practices violate the FTC Act, artificially inflate prices, and make it more difficult for patients to access insulin.

In its administrative complaint, the FTC highlighted that the average list price for commonly used insulin, Humalog, was just $21 in 1999, while it reached more than $274 in 2017. PBMs’ practices are largely to blame for this increase, the complaint alleges. CVS Caremark, Express Scripts, and Optum Rx administer about 80% of all prescriptions in the U.S., giving them significant influence over drug pricing and access.

One legal expert, Lucas Morgan, partner in Frier Levitt’s Healthcare and Life Sciences groups, believes that the FTC might have a favorable outlook in this case. Morgan notes that public sentiment is largely supportive of lowering insulin costs.

However, the PBMs have quickly defended themselves. Elizabeth Hoff, an Optum Rx spokesperson, called the FTC’s action “baseless,” asserting that Optum Rx has worked to lower prescription insulin costs. Similarly, CVS Caremark argued that limiting PBM negotiating tools would reward the pharmaceutical industry and wrongfully blamed drugmakers for their role in the high insulin prices.

Despite the defenses, one national pharma lobby group stated that the FTC’s complaint is strong evidence of how PBMs’ market control increases patient costs and limits access. Nick McGee, DVP public affairs at PhRMA, claims PBMs use savings to boost their profits rather than lowering patient costs.

Should the FTC be successful, the lawsuit notes that the commission could call for several remedies:

  • Prohibit PBMs from excluding or disadvantaging lower wholesale acquisition cost (WAC) versions of high WAC drugs from the same manufacturers when the respondent includes the high WAC drug on a formulary.
  • Ban PBMs from taking compensation based on a drug’s list price.
  • Stop PBMs from designing benefit plans that base patients’ deductibles on the list price rather than the net cost after rebates.

Rahul Rao, deputy director of the FTC Bureau of Competition, noted that this action seeks to end the PBMs’ exploitative conduct. Legal experts argue that the FTC could be favored in these administrative proceedings due to the streamlined and deferential nature of agency proceedings.

This lawsuit is expected to be closely watched by legal professionals across the healthcare and pharmaceutical sectors, given its potential implications on drug pricing and the overall PBM industry.

Read more.